About Event
As Moderna, Merck, BioNTech, and Genentech prepared for high-stakes PCV readouts, the entire field was watching 2025 as a defining year for personalized immunotherapy.
That’s why the 2nd Annual Personalized Cancer Vaccines Summit returned to Boston, as the only strategic forum, dedicated end-to-end to overcoming the scientific, operational, and regulatory complexities of delivering safe, scalable, and effective personalized cancer vaccines.
From mRNA to peptide, viral vector, and dendritic cell platforms, join us in 2026 at your definitive forum to benchmark across modalities, unlock real-world progress, and forge the strategic partnerships needed to get personalized vaccines to patients - faster, smarter, and at scale.
2025's Agenda Was Designed To Answer the Field’s Most Urgent Questions:
• How do we define and validate tumor-specific targets that translate into durable clinical responses across indications?
• What does a manufacturable, scalable, and regulator-ready PCV platform actually look like in 2025?
• Can turnaround time, cost-per-patient, and QC complexity be reduced without compromising precision or safety?
• How are developers redesigning trials in the adjuvant setting, and what evidence will drive approval in low-burden populations?
• Where are immune monitoring, biomarker strategy, and patient selection truly moving the needle?
• What are regulators, payers, and investors actually looking for to back Phase III commitments?
Next year, join 80+ global experts across translational research, manufacturing, clinical development, regulatory, and commercial strategy to shape the future of personalized cancer vaccines - together.